Search

Your search keyword '"Callegaro D"' showing total 317 results
Start Over Author "Callegaro D"
317 results on '"Callegaro D"'

1. Epithelioid hemangioendothelioma, an ultra-rare cancer: a consensus paper from the community of experts

Author

Stacchiotti, S., Miah, A.B., Frezza, A.M., Messiou, C., Morosi, C., Caraceni, A., Antonescu, C.R., Bajpai, J., Baldini, E., Bauer, S., Biagini, R., Bielack, S., Blay, J.Y., Bonvalot, S., Boukovinas, I., Bovee, J.V.M.G., Boye, K., Brodowicz, T., Callegaro, D., De Alava, E., Deoras-Sutliff, M., Dufresne, A., Eriksson, M., Errani, C., Fedenko, A., Ferraresi, V., Ferrari, A., Fletcher, C.D.M., Garcia del Muro, X., Gelderblom, H., Gladdy, R.A., Gouin, F., Grignani, G., Gutkovich, J., Haas, R., Hindi, N., Hohenberger, P., Huang, P., Joensuu, H., Jones, R.L., Jungels, C., Kasper, B., Kawai, A., Le Cesne, A., Le Grange, F., Leithner, A., Leonard, H., Lopez Pousa, A., Martin Broto, J., Merimsky, O., Merriam, P., Miceli, R., Mir, O., Molinari, M., Montemurro, M., Oldani, G., Palmerini, E., Pantaleo, M.A., Patel, S., Piperno-Neumann, S., Raut, C.P., Ravi, V., Razak, A.R.A., Reichardt, P., Rubin, B.P., Rutkowski, P., Safwat, A.A., Sangalli, C., Sapisochin, G., Sbaraglia, M., Scheipl, S., Schöffski, P., Strauss, D., Strauss, S.J., Sundby Hall, K., Tap, W.D., Trama, A., Tweddle, A., van der Graaf, W.T.A., Van De Sande, M.A.J., Van Houdt, W., van Oortmerssen, G., Wagner, A.J., Wartenberg, M., Wood, J., Zaffaroni, N., Zimmermann, C., Casali, P.G., Dei Tos, A.P., and Gronchi, A.

Published
2021
Full Text
View/download PDF

8. Strategies for the Delay of Surgery in the Management of Resectable Hepatobiliary Malignancies during the COVID-19 Pandemic.

Author

Kennecke H., Prenen H., Myrehaug S., Callegaro D., Hallet J., Pessaux P., Teh C., Segelov E., Bennett S., Soreide K., Gholami S., Kennecke H., Prenen H., Myrehaug S., Callegaro D., Hallet J., Pessaux P., Teh C., Segelov E., Bennett S., Soreide K., and Gholami S.

Abstract

Objective: We aimed to review data about delaying strategies for the management of hepatobiliary cancers requiring surgery during the covid-19 pandemic. Background(s): Given the covid-19 pandemic, many jurisdictions, to spare resources, have limited access to operating rooms for elective surgical activity, including cancer, thus forcing deferral or cancellation of cancer surgeries. Surgery for hepatobiliary cancer is high-risk and particularly resource-intensive. Surgeons must critically appraise which patients will benefit most from surgery and which ones have other therapeutic options to delay surgery. Little guidance is currently available about potential delaying strategies for hepatobiliary cancers when surgery is not possible. Method(s): An international multidisciplinary panel reviewed the available literature to summarize data relating to standard-of-care surgical management and possible mitigating strategies to be used as a bridge to surgery for colorectal liver metastases, hepatocellular carcinoma, gallbladder cancer, intrahepatic cholangiocarcinoma, and hilar cholangiocarcinoma. Result(s): Outcomes of surgery during the covid-19 pandemic are reviewed. Resource requirements are summarized, including logistics and adverse effects profiles for hepatectomy and delaying strategies using systemic, percutaneous and radiation ablative, and liver embolic therapies. For each cancer type, the long-term oncologic outcomes of hepatectomy and the clinical tools that can be used to prognosticate for individual patients are detailed. Conclusion(s): There are a variety of delaying strategies to consider if availability of operating rooms decreases. This review summarizes available data to provide guidance about possible delaying strategies depending on patient, resource, institution, and systems factors. Multidisciplinary team discussions should be leveraged to consider patient- and tumour-specific information for each individual case.

Published
2021

9. Ultra-rare sarcomas: A consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entities

Author

Stacchiotti, S, Frezza, AM, Blay, J-Y, Baldini, EH, Bonvalot, S, Bovee, JVMG, Callegaro, D, Casali, PG, Chiang, RC-J, Demetri, GD, Demicco, EG, Desai, J, Eriksson, M, Gelderblom, H, George, S, Gounder, MM, Gronchi, A, Gupta, A, Haas, RL, Hayes-Jardon, A, Hohenberger, P, Jones, KB, Jones, RL, Kasper, B, Kawai, A, Kirsch, DG, Kleinerman, ES, Le Cesne, A, Lim, J, Chirlaque Lopez, MD, Maestro, R, Marcos-Gragera, R, Martin Broto, J, Matsuda, T, Mir, O, Patel, SR, Raut, CP, Razak, ARA, Reed, DR, Rutkowski, P, Sanfilippo, RG, Sbaraglia, M, Schaefer, I-M, Strauss, DC, Sundby Hall, K, Tap, WD, Thomas, DM, van der Graaf, WTA, van Houdt, WJ, Visser, O, von Mehren, M, Wagner, AJ, Wilky, BA, Won, Y-J, Fletcher, CDM, Dei Tos, AP, Trama, A, Stacchiotti, S, Frezza, AM, Blay, J-Y, Baldini, EH, Bonvalot, S, Bovee, JVMG, Callegaro, D, Casali, PG, Chiang, RC-J, Demetri, GD, Demicco, EG, Desai, J, Eriksson, M, Gelderblom, H, George, S, Gounder, MM, Gronchi, A, Gupta, A, Haas, RL, Hayes-Jardon, A, Hohenberger, P, Jones, KB, Jones, RL, Kasper, B, Kawai, A, Kirsch, DG, Kleinerman, ES, Le Cesne, A, Lim, J, Chirlaque Lopez, MD, Maestro, R, Marcos-Gragera, R, Martin Broto, J, Matsuda, T, Mir, O, Patel, SR, Raut, CP, Razak, ARA, Reed, DR, Rutkowski, P, Sanfilippo, RG, Sbaraglia, M, Schaefer, I-M, Strauss, DC, Sundby Hall, K, Tap, WD, Thomas, DM, van der Graaf, WTA, van Houdt, WJ, Visser, O, von Mehren, M, Wagner, AJ, Wilky, BA, Won, Y-J, Fletcher, CDM, Dei Tos, AP, and Trama, A

Abstract

BACKGROUND: Among sarcomas, which are rare cancers, many types are exceedingly rare; however, a definition of ultra-rare cancers has not been established. The problem of ultra-rare sarcomas is particularly relevant because they represent unique diseases, and their rarity poses major challenges for diagnosis, understanding disease biology, generating clinical evidence to support new drug development, and achieving formal authorization for novel therapies. METHODS: The Connective Tissue Oncology Society promoted a consensus effort in November 2019 to establish how to define ultra-rare sarcomas through expert consensus and epidemiologic data and to work out a comprehensive list of these diseases. The list of ultra-rare sarcomas was based on the 2020 World Health Organization classification, The incidence rates were estimated using the Information Network on Rare Cancers (RARECARENet) database and NETSARC (the French Sarcoma Network's clinical-pathologic registry). Incidence rates were further validated in collaboration with the Asian cancer registries of Japan, Korea, and Taiwan. RESULTS: It was agreed that the best criterion for a definition of ultra-rare sarcomas would be incidence. Ultra-rare sarcomas were defined as those with an incidence of approximately ≤1 per 1,000,000, to include those entities whose rarity renders them extremely difficult to conduct well powered, prospective clinical studies. On the basis of this threshold, a list of ultra-rare sarcomas was defined, which comprised 56 soft tissue sarcoma types and 21 bone sarcoma types. CONCLUSIONS: Altogether, the incidence of ultra-rare sarcomas accounts for roughly 20% of all soft tissue and bone sarcomas. This confirms that the challenges inherent in ultra-rare sarcomas affect large numbers of patients.

Published
2021

10. Strategies for the delay of surgery in the management of resectable hepatobiliary malignancies during the COVID-19 pandemic.

Author

Callegaro D., Prenen H., Myrehaug S., Hallet J., Bennett S., Soreide K., Gholami S., Pessaux P., Teh C., Segelov E., Kennecke H., Callegaro D., Prenen H., Myrehaug S., Hallet J., Bennett S., Soreide K., Gholami S., Pessaux P., Teh C., Segelov E., and Kennecke H.

Abstract

Objective We aimed to review data about delaying strategies for the management of hepatobiliary cancers requir-ing surgery during the covid-19 pandemic. Background Given the covid-19 pandemic, many jurisdictions, to spare resources, have limited access to operating rooms for elective surgical activity, including cancer, thus forcing deferral or cancellation of cancer surgeries. Surgery for hepatobiliary cancer is high-risk and particularly resource-intensive. Surgeons must critically appraise which patients will benefit most from surgery and which ones have other therapeutic options to delay surgery. Little guidance is currently available about potential delaying strategies for hepatobiliary cancers when surgery is not possible. Methods An international multidisciplinary panel reviewed the available literature to summarize data relating to standard-of-care surgical management and possible mitigating strategies to be used as a bridge to surgery for colorectal liver metastases, hepatocellular carcinoma, gallbladder cancer, intrahepatic cholangiocarcinoma, and hilar cholangiocarcinoma. Results Outcomes of surgery during the covid-19 pandemic are reviewed. Resource requirements are summarized, including logistics and adverse effects profiles for hepatectomy and delaying strategies using systemic, percutaneous and radiation ablative, and liver embolic therapies. For each cancer type, the long-term oncologic outcomes of hepatectomy and the clinical tools that can be used to prognosticate for individual patients are detailed. Conclusions There are a variety of delaying strategies to consider if availability of operating rooms decreases. This review summarizes available data to provide guidance about possible delaying strategies depending on patient, resource, institution, and systems factors. Multidisciplinary team discussions should be leveraged to consider patient-and tumour-specific information for each individual case.Copyright © 2020 Multimed Inc.

Published
2020

11. Immediate and long-term impact of the COVID-19 pandemic on delivery of surgical services

Author

Soreide, K, Hallet, J, Matthews, JB, Schnitzbauer, AA, Line, PD, Lai, PBS, Otero, J, Callegaro, D, Warner, SG, Baxter, NN, Teh, CSC, Ng-Kamstra, J, Meara, JG, Hagander, L, Lorenzon, L, Soreide, K, Hallet, J, Matthews, JB, Schnitzbauer, AA, Line, PD, Lai, PBS, Otero, J, Callegaro, D, Warner, SG, Baxter, NN, Teh, CSC, Ng-Kamstra, J, Meara, JG, Hagander, L, and Lorenzon, L

Abstract

BACKGROUND: The ongoing pandemic is having a collateral health effect on delivery of surgical care to millions of patients. Very little is known about pandemic management and effects on other services, including delivery of surgery. METHODS: This was a scoping review of all available literature pertaining to COVID-19 and surgery, using electronic databases, society websites, webinars and preprint repositories. RESULTS: Several perioperative guidelines have been issued within a short time. Many suggestions are contradictory and based on anecdotal data at best. As regions with the highest volume of operations per capita are being hit, an unprecedented number of operations are being cancelled or deferred. No major stakeholder seems to have considered how a pandemic deprives patients with a surgical condition of resources, with patients disproportionally affected owing to the nature of treatment (use of anaesthesia, operating rooms, protective equipment, physical invasion and need for perioperative care). No recommendations exist regarding how to reopen surgical delivery. The postpandemic evaluation and future planning should involve surgical services as an essential part to maintain appropriate surgical care for the population during an outbreak. Surgical delivery, owing to its cross-cutting nature and synergistic effects on health systems at large, needs to be built into the WHO agenda for national health planning. CONCLUSION: Patients are being deprived of surgical access, with uncertain loss of function and risk of adverse prognosis as a collateral effect of the pandemic. Surgical services need a contingency plan for maintaining surgical care in an ongoing or postpandemic phase.

Published
2020

13. Immediate and long-term impact of the COVID-19 pandemic on delivery of surgical services

Author

Søreide, K, primary, Hallet, J, additional, Matthews, J B, additional, Schnitzbauer, A A, additional, Line, P D, additional, Lai, P B S, additional, Otero, J, additional, Callegaro, D, additional, Warner, S G, additional, Baxter, N N, additional, Teh, C S C, additional, Ng-Kamstra, J, additional, Meara, J G, additional, Hagander, L, additional, and Lorenzon, L, additional

Published
2020
Full Text
View/download PDF

15. Evolution of transmitted HIV-1 drug resistance and viral subtypes circulation in Italy from 2006 to 2016

Author

Rossetti, B., Giambenedetto, Di, Torti, S, Postorino, C. c., Punzi, M. C., Saladini, G., Gennari, F., Borghi, W. f., Monno, V., Pignataro, L., Polilli, A. R., Colafigli, E., Poggi, M., Tini, A., Zazzi, S., Luca, De, Mellace, A., Capetti, V., Gismondo, A., Biondi, M. R., Mussini, M. L., Pecorari, C., Gianotti, M., Sacchini, N., Parruti, D., Baldelli, F., Zanussi, S., Nerli, A., Lenzi, L., Calzetti, C., Vivarelli, A., Maserati, R., Baldanti, F., Poletti, F., Mondino, V., Malena, M., Cascio, A., Filice, G., Magnani, G., Zerbini, A., Lombardi, F., Gaimbenedetto, Di, Andreoni, S., Montano, M., Vullo, M., Turriziani, V., Gonnelli, O., Boeri, A., Bonora, E., Ghisetti, S., Francisci, D., Grossi, P., Bagnarelli, P., Butini, L., Del, Gobbo, Giacometti, R., Tacconi, A., Callegaro, D., Maggiolo, A., Zoncada, F., Paolini, A., Sighinolfi, E., Colao, L., Corsi, G., Blanc, P., Galli, P., Meraviglia, L., Tosti, P., Bruzzone, A., Setti, B., Penco, M., Biagio, Di, Nencioni, A., Pardelli, C., Arcidiacono, R., Degiuli, I., Gennaro, De, Soria, M., Foc, A., Latella, A., Cosco, S., Malandrin, L., Milini, S., Cicconi, P., Rusconi, P., Micheli, S., the Antiviral Response Cohort Analysis (ARCA) Collaborative Group, Rossetti B., Di Giambenedetto S., Torti C., Postorino M.C., Punzi G., Saladini F., Gennari W., Borghi V., Monno L., Pignataro A.R., Polilli E., Colafigli M., Poggi A., Tini S., Zazzi M., De Luca A., Mellace V., Capetti A., Gismondo M.R., Biondi M.L., Mussini C., Pecorari M., Gianotti N., Sacchini D., Parruti G., Baldelli F., Zanussi S., Nerli A., Lenzi L., Calzetti C., Vivarelli A., Maserati R., Baldanti F., Poletti F., Mondino V., Malena M., Cascio A., Filice G., Magnani G., Zerbini A., Lombardi F., Di Gaimbenedetto S., Andreoni M., Montano M., Vullo V., Turriziani O., Gonnelli A., Boeri E., Bonora S., Ghisetti V., Francisci D., Grossi P., Bagnarelli P., Butini L., del Gobbo R., Giacometti A., Tacconi D., Callegaro A., Maggiolo F., Zoncada A., Paolini E., Sighinolfi L., Colao G., Corsi P., Blanc P., Galli L., Meraviglia P., Tosti A., Bruzzone B., Setti M., Penco G., Di Biagio A., Nencioni C., Pardelli R., Arcidiacono I., Degiuli A., De Gennaro M., Soria A., Foc A., Latella S., Cosco L., Malandrin S., Milini P., Cicconi P., Rusconi S., and Micheli V.

Subjects
0301 basic medicine, Male, antiretroviral therapy, HIV, recent HIV infection, resistance epidemiology, transmitted HIV drug resistance, Adult, Anti-HIV Agents, CD4 Lymphocyte Count, Female, HIV Infections, HIV-1, Humans, Italy, Middle Aged, Mutation, Odds Ratio, Prevalence, Viral Proteins, Drug Resistance, Viral, Health Policy, Infectious Diseases, Pharmacology (medical), Drug Resistance, Drug resistance, Gastroenterology, Interquartile range, HIV Infection, Viral, biology, Integrase, Viral load, Human, medicine.medical_specialty, 030106 microbiology, Settore MED/17 - MALATTIE INFETTIVE, Virus, 03 medical and health sciences, Internal medicine, medicine, Viral Protein, business.industry, Anti-HIV Agent, Odds ratio, Reverse transcriptase, Confidence interval, biology.protein, business
Abstract

Objectives: The aim was to evaluate the evolution of transmitted HIV-1 drug resistance (TDR) prevalence in antiretroviral therapy (ART)-naïve patients from 2006 to 2016. Methods: HIV-1 sequences were retrieved from the Antiviral Response Cohort Analysis (ARCA) database and TDR was defined as detection of at least one mutation from the World Health Organization (WHO) surveillance list. Results: We included protease/reverse transcriptase sequences from 3573 patients; 455 had also integrase sequences. Overall, 68.1% of the patients were Italian, the median CD4 count was 348 cells/μL [interquartile range (IQR) 169–521 cells/μL], and the median viral load was 4.7 log 10 HIV-1 RNA copies/mL (IQR 4.1–5.3 log 10 copies/mL). TDR was detected in 10.3% of patients: 6% carried mutations to nucleos(t)ide reverse transcriptase inhibitors (NRTIs), 4.4% to nonnucleos(t)ide reverse transcriptase inhibitors (NNRTIs), 2.3% to protease inhibitors (PIs), 0.2% to integrase strand transfer inhibitors (INSTIs) and 2.1% to at least two drug classes. TDR declined from 14.5% in 2006 to 7.3% in 2016 (P=0.003): TDR to NRTIs from 9.9 to 2.9% (P=0.003) and TDR to NNRTIs from 5.1 to 3.7% (P=0.028); PI TDR remained stable. The proportion carrying subtype B virus declined from 76.5 to 50% (P&nbsp

Published
2018

16. OC-0070 Radiation Therapy for Retroperitoneal Liposarcoma – A report from TARPSWG

Author

Haas, R., primary, Bonvalot, S., additional, Miceli, R., additional, Strauss, D., additional, Swallow, C., additional, Hohenberger, P., additional, Van Coevorden, F., additional, Rutkowski, P., additional, Callegaro, D., additional, Hayes, A., additional, Honoré, C., additional, Fairweather, M., additional, Gladdy, R., additional, Jakob, J., additional, Szacht, M., additional, Fiore, M., additional, Chung, P., additional, Van Houdt, W., additional, Raut, C., additional, and Gronchi, A., additional

Published
2019
Full Text
View/download PDF

17. Management of Recurrent Retroperitoneal Sarcoma (RPS) in the Adult: A Consensus Approach from the Trans-Atlantic RPS Working Group (vol 23, pg 3531, 2016)

Author

Ahlen, J., Ahuja, N., Antbacka, R., Bagaria, S., Blay, J.Y., Bonvalot, S., Callegaro, D., Canter, R.J., Cardona, K., Casali, P.G., Colombo, C., Tos, A.P.D., Paoli, A. de, Desai, A., Dickson, B.C., Eilber, F.C., Fiore, M., Fletcher, C.D., Ford, S.J., Gelderblom, H.J., Gonzalez, R., Grignani, G., Grignol, V., Gronchi, A., Haas, R.L., Hayes, A.J., Hartmann, W., Henzler, T., Hohenberger, P., Italiano, A., Jakob, J., Jones, R.L., Judson, I., Kane, J.M., Lahat, G., MacNeill, A.J., Maestro, R., Messiou, C., Meeus, P., Miceli, R., Mullen, J.T., Nessim, C., Pennacchioli, E., Pillarisetty, V.G., Pollock, R.E., Quagliuolo, V., Radaelli, S., Raut, C.P., Rutkowski, P., Sandrucci, S., Schrage, Y.M., Sicklick, J.K., Smith, M.J., Stacchiotti, S., Stoeckle, E., Strauss, D.C., Swallow, C.J., Tseng, W., Wardelmann, E., Coevorden, F. van, Houdt, W.J. van, Wasif, N., and Trans-Atlantic RPS Working Grp

Published
2017

18. METABOLIC MYOPATHIES I

Author

Silva, A., primary, Mendonça, R., additional, Soares, D., additional, Callegaro, D., additional, Caldas, V., additional, Carvalho, M., additional, and Zanoteli, E., additional

Published
2018
Full Text
View/download PDF

19. Management of Recurrent Retroperitoneal Sarcoma (RPS) in the Adult: A Consensus Approach from the Trans-Atlantic RPS Working Group

Author

Ahlen, J., Ahuja, N., Antbacka, R., Bagaria, S., Blay, J.Y., Bonvalot, S., Callegaro, D., Canter, R.J., Cardona, K., Casali, P.G., Colombo, C., Tos, A.P. dei, Paoli, A. de, Desai, A., Dickson, B.C., Eilber, F.C., Fiore, M., Fletcher, C.D., Ford, S.J., Gelderblom, H.J., Gonzalez, R., Grignani, G., Grignol, V., Gronchi, A., Haas, R.L., Hayes, A.J., Hartmann, W., Henzler, T., Hohenberger, P., Italiano, A., Jakob, J., Jones, R.L., Judson, I., Kane, J.M., Lahat, G., MacNeill, A.J., Maestro, R., Messiou, C., Meeus, P., Miceli, R., Mullen, J.T., Nessim, C., Pennacchioli, E., Pillarisetty, V.G., Pollock, R.E., Quagliuolo, V., Radaelli, S., Raut, C.P., Rutkowski, P., Sandrucci, S., Schrage, Y.M., Sicklick, J.K., Smith, M.J., Stacchiotti, S., Stoeckle, E., Strauss, D.C., and Trans-Atlantic RPS Working Grp

Subjects
Leiomyosarcoma, Adult, medicine.medical_specialty, Consensus, Undifferentiated Pleomorphic Sarcoma, Article, 03 medical and health sciences, 0302 clinical medicine, Carcinosarcoma, medicine, Humans, Retroperitoneal Neoplasms, Sarcomatoid carcinoma, business.industry, General surgery, Fibromatosis, Sarcoma, medicine.disease, Combined Modality Therapy, Surgery, Oncology, 030220 oncology & carcinogenesis, Practice Guidelines as Topic, 030211 gastroenterology & hepatology, Clear-cell sarcoma, Embryonal rhabdomyosarcoma, Neoplasm Recurrence, Local, business
Abstract

Retroperitoneal soft tissue sarcomas (RPS) are rare tumors. Surgery is the mainstay of curative therapy, but local recurrence is common. No recommendations concerning the best management of recurring disease have been developed so far. Although every effort should be made to optimize the initial approach, recommendations to treat recurring RPS will be helpful to maximize disease control at recurrence. An RPS transatlantic working group was established in 2013. The goals of the group were to share institutional experiences, build large multi-institutional case series, and develop consensus documents on the approach to this difficult disease. The outcome of this document applies to recurrent RPS that is nonvisceral in origin. Included are sarcomas of major veins, undifferentiated pleomorphic sarcoma of psoas, ureteric leiomyosarcoma (LMS). Excluded are desmoids-type fibromatosis, angiomyolipoma, gastrointestinal stromal tumors, sarcomas arising from the gut or its mesentery, uterine LMS, prostatic sarcoma, paratesticular/spermatic cord sarcoma, Ewing sarcoma, alveolar/embryonal rhabdomyosarcoma, sarcoma arising from teratoma, carcinosarcoma, sarcomatoid carcinoma, clear cell sarcoma, radiation-induced sarcoma, paraganglioma, and malignant pheochromocytoma. Recurrent RPS management was evaluated from diagnosis to follow-up. It is a rare and complex malignancy that is best managed by an experienced multidisciplinary team in a specialized referral center. The best chance of cure is at the time of primary presentation, but some patients may experience prolonged disease control also at recurrence, when the approach is optimized and follows the recommendations contained herein. International collaboration is critical for adding to the present knowledge. A transatlantic prospective registry has been established.

Published
2016

22. External validation of a multi-institutional retroperitoneal sarcoma nomogram

Author

Cp, Raut, Miceli R, Dc, Strauss, Cj, Swallow, Hohenberger P, van Coevorden F, Rutkowski P, Fiore M, Callegaro D, Pg, Casali, Rl, Haas, Aj, Hayes, Honore C, Aj, Cannell, Jakob J, Szacht M, Fairweather M, Re, Pollock, Bonvalot S, and Alessandro Gronchi

Subjects
grade, histology, nomogram, surgery, staging, multifocality, retroperitoneal sarcoma
Published
2016

27. Resectable extra-pleural and extra-meningeal solitary fibrous tumours: A multi-centre prognostic study

Author

Pasquali, S., primary, Gronchi, A., additional, Strauss, D., additional, Bonvalot, S., additional, Jeys, L., additional, Stacchiotti, S., additional, Hayes, A., additional, Honore, C., additional, Collini, P., additional, Renne, S.L., additional, Alexander, N., additional, Grimer, R.J., additional, Callegaro, D., additional, Sumathi, V.P., additional, Gourevitch, D., additional, and Desai, A., additional

Published
2016
Full Text
View/download PDF

28. Os centros de saúde mental na Itália

Author

Furlan, Piermaria, Rosa, M, Moncalvo, Marta, Caporale, D, Matrone, L, Olanda, I, Callegaro, D, PORTIGLIATTI POMERI, A, Costa, G, Zuffranieri, M, Ozzello, D, Stanga, F, and Picci, Rocco Luigi

Subjects
Mental Health, Community mental health services, Health
Published
2012

31. 3404 External validation of a nomogram predicting disease-free (DFS) and overall survival (OS) in patients (pts) with primary retroperitoneal sarcoma (pRPS)

Author

Raut, C., primary, Miceli, R., additional, Strauss, D., additional, Swallow, C., additional, Hohenberger, P., additional, Coevorden, F. Van, additional, Rutkowski, P., additional, Fiore, M., additional, Callegaro, D., additional, Casali, P., additional, Haas, R., additional, Hayes, A., additional, Honore, C., additional, Cannell, A., additional, Jakob, J., additional, Szacht, M., additional, Fairweather, M., additional, Pollock, R., additional, Bonvalot, S., additional, and Gronchi, A., additional

Published
2015
Full Text
View/download PDF

32. 250 mu g or 500 mu g interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study

Author

O'Connor, P., Filippi, M., Arnason, B., Comi, G., Cook, S., Goodin, D., Hartung, H., Jeffery, D., Kappos, L., Boateng, F., Filippov, V., Groth, M., Knappertz, V., Kraus, C., Sandbrink, R., Pohl, C., BogumilAbramsky O, T., Achiron, A, Agius, M, Aichner, F, Altenkirch, H, Amato, Mp, Anten, B, Arbizu, T, Ash, P, Ballario, C, Bashir, K, Baum, K, Baumhackl, U, Beaver, G, Belova, A, Berger, J, Berger, T, Berlit, P, Beuche, W, Bhan, V, Bigley, K, Bissay, V, Blake, C, Bö, L, Boyko, A, Brochet, B, Brown, M, Callegaro, D, Carra, A, Carroll, W, Cascione, M, Christie, S, Clanet, M, Clavelou, P, Clementino, Vi, Confavreux, C, Cooper, J, Cross, A, Csanyi, A, Czlonkowska, A, D'Hooghe, M, Damier, P, Debouverie, M, Defer, G, Demina, T, Deri, N, Diem, R, Dressel, A, Dubois, B, Dunne, P, Duquette, P, Durelli, L, Edan, G, Elias, S, Elovaara, I, Esfahani, F, Evtushenko, S, Fabijan, Th, Fernández, O, Ferreira, Ml, Fink, A, Flechter, S, Ford, C, Francesconi, C, Freedman, M, Fryze, W, Gabbai, A, Gács, G, Gallo, Paolo, Gazda, S, Gerloff, C, Glyman, S, Goodman, A, Gottesman, M, Grand'Maison, F, Guarnaccia, J, Gutierrez, A, Haas, J, Hansen, Hj, Hardiman, O, Heard, R, Heidenreich, F, Herbert, J, Herminia Scola, R, Hodgkinson, S, Hoffmann, F, Holub, R, Huddlestone, J, Hughes, B, Hughes, M, Hunter, S, Hurwitz, B, Izquierdo, G, Jacobasch, E, Jacques, F, Jakab, G, Jongen, P, Karageorgiou, C, Karni, A, Kasper, L, Kaufman, M, Keidel, M, Khatri, B, Kiefer, R, Kirzinger, S, Kita, M, Komoly, S, Kotov, S, Kozubski, W, Kumlien, E, Kwiecinski, H, Labouge, P, Laganke, C, Lapierre, Y, Lebrun Frenay, C, Leist, T, Leon, Sa, Luetic, G, Lynch, S, Lynch, T, Malkova, N, Maltezou, M, Markowitz, C, Martin, C, Mattle, H, Mattson, D, Metra, M, Meyding Lamadé, U, Milo, R, Milonas, I, Miller, A, Miller, T, Minagar, A, Mitchell, G, Moreau, T, Mosberg, R, Murphy, R, Nehrych, T, Nikl, J, Odinak, M, Oschmann, P, Owen King, J, Pagani, L, Pereira Damasceno, B, Podemski, R, Pöhlau, D, Pozzilli, C, Rammohan, K, Reunanen, M, Rice, G, Richardson, P, Rivera, V, Rizvi, S, Rogozhyn, V, Rolak, L, Rosenkranz, T, Rotta, R, Sanders, E, Sater, R, Satgur Gupta, A, Schwartz, R, Sedal, L, Sega Jazbec, S, Selchen, D, Selmaj, K, Sheremata, W, Shvets, T, Silver, D, Simsarian, J, Skoromets, A, Smiroldo, J, Sokolova, L, Solovyova, Y, Sommer, N, Spirin, N, Stangel, M, Stark, E, Steinbrecher, A, Stemper, B, Stolyarov, I, Strasser Fuchs, S, Sweeney, B, Tettenborn, B, Thrower, B, Tilbery, Cp, Traboulsee, A, Trojano, M, Tubridy, N, Tyor, W, Valikovics, A, Vermersch, P, Vollmer, T, Voloshyna, N, Vrech, C, Wajgt, A, Weller, B, Wendt, J, Yakhno, N, Yeung, M, Zavalishin, I., O'Connor, P, Filippi, Massimo, Arnason, B, Comi, G, Cook, S, Goodin, D, Hartung, Hp, Jeffery, D, Kappos, L, Boateng, F, Filippov, V, Groth, M, Knappertz, V, Kraus, C, Sandbrink, R, Pohl, C, Bogumil, T., and Dubois, Bénédicte

Subjects
Adult, Male, medicine.medical_specialty, interferon beta-1b, Adolescent, Pharmacology, relapsing-remitting multiple sclerosis, law.invention, Young Adult, Multiple Sclerosis, Relapsing-Remitting, Randomized controlled trial, Double-Blind Method, law, Internal medicine, medicine, Humans, Immunologic Factors, Glatiramer acetate, Adverse effect, Expanded Disability Status Scale, Dose-Response Relationship, Drug, business.industry, Multiple sclerosis, Interferon beta-1b, Brain, Glatiramer Acetate, Interferon-beta, Middle Aged, medicine.disease, Magnetic Resonance Imaging, Clinical trial, Tolerability, glatiramer acetate, Female, Neurology (clinical), business, Peptides, medicine.drug
Abstract

BACKGROUND: The aim of the Betaferon Efficacy Yielding Outcomes of a New Dose (BEYOND) trial was to compare the efficacy, safety, and tolerability of 250 microg or 500 microg interferon beta-1b with glatiramer acetate for treating relapsing-remitting multiple sclerosis. METHODS: Between November, 2003, and June, 2005, 2447 patients with relapsing-remitting multiple sclerosis were screened and 2244 patients were enrolled in this prospective, multicentre, randomised trial. Patients were randomly assigned 2:2:1 by block randomisation with regional stratification to receive one of two doses of interferon beta-1b (250 microg or 500 microg) subcutaneously every other day or 20 mg glatiramer acetate subcutaneously every day. The primary outcome was relapse risk, defined as new or recurrent neurological symptoms separated by at least 30 days from the preceding event and that lasted at least 24 h. Secondary outcomes were progression on the expanded disability status scale (EDSS) and change in T1-hypointense lesion volume. Clinical outcomes were assessed quarterly for 2.0-3.5 years; MRI was done at screening and annually thereafter. Analysis was by per protocol. This study is registered, number NCT00099502. FINDINGS: We found no differences in relapse risk, EDSS progression, T1-hypointense lesion volume, or normalised brain volume among treatment groups. Flu-like symptoms were more common in patients treated with interferon beta-1b (p

Published
2009

38. Myasthenia gravis and neuromyelitis optica spectrum disorder: A multicenter study of 16 patients

Author

Leite, M. I., primary, Coutinho, E., additional, Lana-Peixoto, M., additional, Apostolos, S., additional, Waters, P., additional, Sato, D., additional, Melamud, L., additional, Marta, M., additional, Graham, A., additional, Spillane, J., additional, Villa, A. M., additional, Callegaro, D., additional, Santos, E., additional, da Silva, A. M., additional, Jarius, S., additional, Howard, R., additional, Nakashima, I., additional, Giovannoni, G., additional, Buckley, C., additional, Hilton-Jones, D., additional, Vincent, A., additional, and Palace, J., additional

Published
2012
Full Text
View/download PDF

41. CS.2.7 PALLIATIVE ENDOSCOPIC TREATMENT BY SELF EXPANDING METAL STENT (SEMS) IN PATIENTS WITH INOPERABLE MALIGNANT COLORECTAL OBSTRUCTION. ANALYSIS OF RESULTS AND PREDICTORS OF OUTCOMES IN A LARGE MULTICENTER SERIES

Author

Manes, G., primary, de Bellis, M., additional, Masci, E., additional, Cennamo, V., additional, Tempesta, A., additional, Fuccio, L., additional, Mangiavillano, B., additional, Ardizzone, S., additional, Callegaro, D., additional, Viaggi, P., additional, Sandomenico, C., additional, and Bazzoli, F., additional

Published
2010
Full Text
View/download PDF

50. Recurrent neuromyelitis optica in Brazilian patients: clinical, immunological, and neuroimaging characteristics.

Author

Adoni, T., Lino, A. M. M., da Gama, P. D., Apóstolos-Pereira, S. L., Marchiori, P. E., Kok, F., and Callegaro, D.

Subjects
BRAIN imaging, ANTIGENS, AQUAPORINS, RESPIRATORY diseases, PRECANCEROUS conditions
Abstract

Neuromyelitis optica has not been thoroughly studied in Brazilian patients following the discovery of NMO-IgG and its specific antigen aquaporin-4. In this study we aimed to describe the clinical NMO-IgG immunological status and neuroimaging characteristics of recurrent neuromyelitis optica in a series Brazilian patients. We undertook a retrospective study of 28 patients with recurrent neuromyelitis optica, according to 1999 Wingerchuk's diagnostic criteria. Data on NMO-IgG status, clinical features, and MRI findings were analyzed. Three men and 25 women were evaluated. Median age at onset of disease was 26 years (range 7-55); median time of follow-up was 7 years (range 2-14). The mean time elapsed between the first and the second attack was 17 months (median 8.5; range 2-88). NMO-IgG was detected in 18 patients (64.3%). Four patients died due to respiratory failure. Most patients presented with cervical (36%) and cervical-thoracic myelitis (46.4%). Holocord lesion was the most common pattern of involvement (50%) on the axial plane. We did not find a statistical association between myelitis extension and NMO-IgG result. Our series of Brazilian patients showed a younger age of onset than previously reported. In our series, in contrast to previous reports, there was no correlation between the extension of myelitis and NMO-IgG positivity. [ABSTRACT FROM AUTHOR]

Published
2010
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results